35th Annual New Treatments in Chronic Liver Disease 2021

35th Annual New Treatments in Chronic Liver Disease 2021 is organized by Scripps Conference Services & CME. This Onsite medical conference will be held from Mar 19 - 21, 2021 at San Diego Mission Bay Resort, San Diego, California, United States of...
Gastroenterolog...
35th Annual New Treatments in Chronic Liver Disease 2021 is organized by Scripps Conference Services & CME. This Onsite medical conference will be held from Mar 19 - 21, 2021 at San Diego Mission Bay Resort, San Diego, California, United States of America. Accreditation: Physicians Scripps Health assigns this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians will be able to earn the credit commensurate with the extent of their participation in the activity. ABIM MOC Points Successful completion of this CME activity, which constitutes participation in the evaluation component, allowing the participant to earn up to 13.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Credit Breakdown: • Pre-Conference (Fri): 3.5 • Main Conference (Sat-Sun): 10 American Academy of Physician Assistants PAs may earn a maximum of 13.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations authorized by ACCME or a recognized state medical society. Course Overview This CME conference will evaluate distinct medications and therapies that are now available, or will soon be available, and present their comparative values. The results of examinations and real-world data utilizing oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma, and complexities of end-stage liver disease along with the thrombocytopenia will be examined in detail. New Treatments in Chronic Liver Disease is a thorough yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases. Educational Objectives At the conclusion of this live activity, participants should be able to: • Know the steps demanded to achieve the eradication of chronic viral hepatitis by 2030. • Examine prevailing knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to the treatment of the conditions. • Combine the algorithm for a therapeutic approach to the treatment of HBV using anti-virals. • Express the diagnosis, management, and treatment of unusual hepatitis virus infections. • Refresh the skills and management required for transplant hepatology. • Employ current options of therapy for hepatocellular carcinoma to determine the best approach for your patients. • Explain the diagnosis and treatment of PBC and PSC. • Integrate treatment options considered for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH, or inherited genetic disorders. • Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy, and hyponatremia. • Update the diagnosis and management of benign masses in the liver. • Examine the increasing burden of alcoholic liver disease in the United States. • Review advances in the treatment of acute liver failure.
support@emedevents.com
1(800) 828-2059
San Diego, California